258 related articles for article (PubMed ID: 31808966)
1. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
[TBL] [Abstract][Full Text] [Related]
2. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
[TBL] [Abstract][Full Text] [Related]
4. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
5. [Effects of glycogen synthase kinase 3β overexpression in rat and glycogen synthase kinase 3β inhibitor SB-216763 on proliferation of hepatic oval cells].
Zhong JQ; Xie YK; Ji XK; Fu JH; Wang Y; Zhang QY; Shi HQ; Shan YF
Zhonghua Wai Ke Za Zhi; 2012 Nov; 50(11):1003-6. PubMed ID: 23302485
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin induces G
Chen MJ; Cheng AC; Lee MF; Hsu YC
J Cell Physiol; 2018 Jun; 233(6):4618-4625. PubMed ID: 28833099
[TBL] [Abstract][Full Text] [Related]
9. GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells.
Liu SL; Liu Z; Zhang LD; Zhu HQ; Guo JH; Zhao M; Wu YL; Liu F; Gao FH
Cell Cycle; 2017; 16(24):2386-2395. PubMed ID: 28980866
[TBL] [Abstract][Full Text] [Related]
10. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.
Yu AS; Zhao L
Tumour Biol; 2016 Apr; 37(4):4857-64. PubMed ID: 26526575
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin.
Shimozaki S; Yamamoto N; Domoto T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Miwa S; Igarashi K; Kato T; Aoki Y; Higuchi T; Hirose M; Hoffman RM; Minamoto T; Tsuchiya H
Oncotarget; 2016 Nov; 7(47):77038-77051. PubMed ID: 27780915
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
[TBL] [Abstract][Full Text] [Related]
13. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
14. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
[TBL] [Abstract][Full Text] [Related]
16. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
Hong M; Almutairi MM; Li S; Li J
Phytomedicine; 2020 Mar; 68():153174. PubMed ID: 31991293
[TBL] [Abstract][Full Text] [Related]
17. β-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3β/β-catenin signaling.
Chen J; Ko J; Kim JT; Cho JS; Qiu S; Kim GD; Auh JH; Lee HJ
Food Funct; 2019 May; 10(5):2691-2700. PubMed ID: 31026007
[TBL] [Abstract][Full Text] [Related]
18. Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3β/cyclin D1 pathway.
Wang J; Li XM; Bai Z; Chi BX; Wei Y; Chen X
J Ethnopharmacol; 2018 Jan; 210():1-9. PubMed ID: 28684297
[TBL] [Abstract][Full Text] [Related]
19. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.
Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD
Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223
[TBL] [Abstract][Full Text] [Related]
20. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
Ugolkov AV; Bondarenko GI; Dubrovskyi O; Berbegall AP; Navarro S; Noguera R; O'Halloran TV; Hendrix MJ; Giles FJ; Mazar AP
Anticancer Drugs; 2018 Sep; 29(8):717-724. PubMed ID: 29846250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
